World's First Dual-Payload ADC KH815 Enters Clinical Trials with BioDlink Manufacturing Support
核心洞察
Chengdu Kanghong Pharmaceutical's KH815 becomes the world's first dual-payload antibody-drug conjugate to enter clinical development, receiving regulatory approval in Australia and China.
BioDlink (搜索)'s CDMO services enabled IND approval 1.5 months ahead of schedule through advanced process development and analytical control for the complex first-in-class program.
The milestone demonstrates the growing potential of dual-payload ADC technologies and highlights successful industry collaboration in advancing next-generation cancer therapeutics.
Chengdu Kanghong Pharmaceutical Group (搜索) has achieved a significant milestone in oncology (搜索) drug development with KH815, the world's first dual-payload antibody-drug conjugate (ADC) to enter clinical trials. The first-in-class therapeutic received approval from Australia's Human Research Ethics Committee (HREC) on March 21, 2025, followed by clinical trial authorization in China on April 15, 2025.
BioDlink (搜索), the contract development and manufacturing organization (CDMO) supporting the program, received formal recognition from Kanghong Pharmaceutical for enabling the accelerated timeline. The collaboration resulted in IND approval 1.5 months ahead of the original schedule through efficient process development, manufacturing, and analytical execution.
Advanced Manufacturing Challenges
The development of KH815 presented unique technical challenges requiring sophisticated process design and analytical control. The dual-payload ADC demanded precise management of drug-to-antibody ratio (DAR) and comprehensive product characterization, significantly more complex than traditional single-payload conjugates.
BioDlink (搜索) leveraged its expertise in complex ADC development to deliver a robust, scalable, and reproducible manufacturing solution despite limited material availability and aggressive timelines. The company's technical team successfully defined and locked robust process and analytical strategies, enabling successful scale-up and batch release for the innovative therapeutic.
Regulatory Pathway Success
The regulatory success of KH815 represents a breakthrough for dual-payload ADC technology, demonstrating that complex bioconjugates can navigate approval pathways efficiently with proper development support. BioDlink (搜索)'s comprehensive services spanned the full development lifecycle, including process development, analytical method development and validation, and formulation research.
Through continuous process optimization, the development team completed manufacturing and regulatory submission activities significantly ahead of schedule, exceeding client expectations and earning recognition for technical expertise and service excellence from Kanghong Pharmaceutical.
Industry Impact
The successful progression of KH815 into clinical trials underscores the growing potential of dual-payload ADC technologies in addressing unmet medical needs in oncology (搜索). This achievement highlights the critical value of specialized CDMO partnerships in advancing complex biologics from research through clinical development.
BioDlink (搜索)'s role in enabling this first-in-class program demonstrates the company's capabilities in supporting innovative bioconjugate development. The CDMO operates four commercial manufacturing lines with large-scale sterile fill-finish capabilities, backed by a global GMP-aligned quality system that has earned PMDA accreditation in Japan and supported product approvals across multiple countries including China, Indonesia, Nigeria, Pakistan, Colombia, and Bolivia.
The milestone represents a significant step forward for both companies, with Kanghong Pharmaceutical advancing its pipeline of innovative therapeutics for ophthalmic and neuropsychiatric conditions, while BioDlink (搜索) continues to establish itself as a leader in complex biologics manufacturing and development services.